Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (451-460 of 477) with videos related to

Pageof 48
Sort By:
Clinical and Experimental Rheumatology|December 3, 2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registryLorinda Chung, Robert M Fairchild, Daniel E Furst, et al.
Annals of the American Thoracic Society|April 15, 2016
Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center ExperienceCatherine H Miele, Kristin Schwab, Rajeev Saggar, et al.
The New England Journal of Medicine|February 24, 2006
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritisDaniel O Clegg, Domenic J Reda, Crystal L Harris, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
The Journal of Rheumatology|February 15, 2007
Outcome measurements in scleroderma: results from a delphi exerciseHashim Gazi, Janet E Pope, Philip Clements, et al.
Arthritis Care & Research|October 2, 2012
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaDinesh Khanna, John D Fitzgerald, Puja P Khanna, et al.
Arthritis Care & Research|October 2, 2012
2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritisDinesh Khanna, Puja P Khanna, John D Fitzgerald, et al.
Plos One|January 3, 2018
Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populationsOlga Y Gorlova, Yafang Li, Ivan Gorlov, et al.
Pageof 48

Showing results (451-460 of 477) with videos related to

Sort By:
Pageof 48
Clinical and Experimental Rheumatology|December 3, 2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registryLorinda Chung, Robert M Fairchild, Daniel E Furst, et al.
Annals of the American Thoracic Society|April 15, 2016
Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center ExperienceCatherine H Miele, Kristin Schwab, Rajeev Saggar, et al.
The New England Journal of Medicine|February 24, 2006
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritisDaniel O Clegg, Domenic J Reda, Crystal L Harris, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Journal of Scleroderma and Related Disorders|September 25, 2023
Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentCosimo Bruni, Maya H Buch, Aleksandra Djokovic, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
The Journal of Rheumatology|February 15, 2007
Outcome measurements in scleroderma: results from a delphi exerciseHashim Gazi, Janet E Pope, Philip Clements, et al.
Arthritis Care & Research|October 2, 2012
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaDinesh Khanna, John D Fitzgerald, Puja P Khanna, et al.
Arthritis Care & Research|October 2, 2012
2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritisDinesh Khanna, Puja P Khanna, John D Fitzgerald, et al.
Plos One|January 3, 2018
Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populationsOlga Y Gorlova, Yafang Li, Ivan Gorlov, et al.
Pageof 48